Phase I/II trial of induction carboplatin/paclitaxel with bevacizumab followed by concurrent thoracic conformal radiation therapy with carboplatin/paclitaxel, bevacizumab and erlotinib in stage IIIA/B non-small cell lung cancer (NSCLC).

Trial Profile

Phase I/II trial of induction carboplatin/paclitaxel with bevacizumab followed by concurrent thoracic conformal radiation therapy with carboplatin/paclitaxel, bevacizumab and erlotinib in stage IIIA/B non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Bevacizumab; Carboplatin; Erlotinib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2011 Planned end date added (Jan 2017) as reported by ClinicalTrials.gov.
    • 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top